DK1812476T3 - Anti-IL-22RA-antistoffer og bindingspartnere samt fremgangsmåder til anvendelse ved inflammation - Google Patents

Anti-IL-22RA-antistoffer og bindingspartnere samt fremgangsmåder til anvendelse ved inflammation

Info

Publication number
DK1812476T3
DK1812476T3 DK05816060.7T DK05816060T DK1812476T3 DK 1812476 T3 DK1812476 T3 DK 1812476T3 DK 05816060 T DK05816060 T DK 05816060T DK 1812476 T3 DK1812476 T3 DK 1812476T3
Authority
DK
Denmark
Prior art keywords
antibodies
binding partners
methods
well
inflammation
Prior art date
Application number
DK05816060.7T
Other languages
English (en)
Inventor
Wenfeng Xu
Wayne R Kindsvogel
Yasmin A Chandrasekher
Stacey R Dillon
Joyce M Lehner
Margaret D Moore
Pallavur V Sivakumar
Anthony W Siadak
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of DK1812476T3 publication Critical patent/DK1812476T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
DK05816060.7T 2004-10-22 2005-10-21 Anti-IL-22RA-antistoffer og bindingspartnere samt fremgangsmåder til anvendelse ved inflammation DK1812476T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62155304P 2004-10-22 2004-10-22
PCT/US2005/037821 WO2006047249A1 (en) 2004-10-22 2005-10-21 Anti-il-22ra antibodies and binding partners and methods of using in inflammation

Publications (1)

Publication Number Publication Date
DK1812476T3 true DK1812476T3 (da) 2010-10-25

Family

ID=35871017

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05816060.7T DK1812476T3 (da) 2004-10-22 2005-10-21 Anti-IL-22RA-antistoffer og bindingspartnere samt fremgangsmåder til anvendelse ved inflammation

Country Status (22)

Country Link
US (5) US7537761B2 (da)
EP (1) EP1812476B1 (da)
JP (1) JP4898691B2 (da)
KR (1) KR101238684B1 (da)
CN (1) CN101198625A (da)
AT (1) ATE474856T1 (da)
AU (1) AU2005299809B2 (da)
BR (1) BRPI0516975A (da)
CA (1) CA2584157C (da)
CY (1) CY1110843T1 (da)
DE (1) DE602005022475D1 (da)
DK (1) DK1812476T3 (da)
EA (1) EA015706B1 (da)
ES (1) ES2347672T3 (da)
HK (1) HK1110333A1 (da)
IL (2) IL182503A (da)
MX (1) MX2007004770A (da)
NO (1) NO20072602L (da)
PT (1) PT1812476E (da)
UA (1) UA96122C2 (da)
WO (1) WO2006047249A1 (da)
ZA (1) ZA200704125B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965704A (en) * 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
CA2418950A1 (en) * 2000-08-08 2002-02-14 Zymogenetics, Inc. Soluble zcytor 11 cytokine receptors
US20060134756A1 (en) * 2003-03-24 2006-06-22 Wenfeng Xu Anti-IL-20 antibodies and binding partners and methods of using in inflammation
EP1697418A2 (en) * 2003-11-21 2006-09-06 ZymoGenetics, Inc. Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation
US7537761B2 (en) * 2004-10-22 2009-05-26 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
RU2426742C2 (ru) * 2005-12-02 2011-08-20 Дженентек, Инк. Составы и способы лечения заболеваний и нарушений, связанных с передачей сигналов цитокинами
WO2011047153A1 (en) * 2009-10-15 2011-04-21 President And Fellows Of Harvard College Methods for modulating autoimmunity
EP2512511B1 (en) 2009-11-19 2015-01-07 Merck Serono S.A. Humanized antibodies against human il-22ra
WO2011104381A2 (en) 2010-02-26 2011-09-01 Novo Nordisk A/S Stable antibody containing compositions
MX2012013586A (es) 2010-05-28 2013-01-24 Novo Nordisk As Composiciones multi-dosis estables que comprenden un anticuerpo y un conservante.
EP2661279A4 (en) 2011-01-04 2015-09-09 Us Health METHODS OF TREATING AGE-RELATED MACULAR DEGENERATION
WO2012123586A1 (en) 2011-03-16 2012-09-20 arGEN-X BV Antibodies to cd70
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
US11510966B2 (en) * 2016-04-15 2022-11-29 Evive Biotechnology (Shanghai) Ltd Use of IL-22 in treating necrotizing enterocolitis
WO2017202813A1 (en) 2016-05-24 2017-11-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of pulmonary bacterial infections
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
CN110402393A (zh) * 2016-11-24 2019-11-01 休伯特保健公司 疾病诊断的组合物
CN112292396A (zh) 2018-06-05 2021-01-29 生物蛋白有限公司 抗il-22抗体，抗体片段，其免疫结合物及其用途
CN110078832B (zh) * 2019-04-18 2021-12-14 江南大学 一类基于ZZ domain的二抗及其制备方法和应用
MX2023010238A (es) * 2021-03-02 2023-12-05 Dana Farber Cancer Inst Inc Métodos para tratar trastornos de glóbulos rojos.

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090A (en) * 1968-09-24 1972-04-04 Organon Method for the determination of antigens and antibodies
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
NZ212437A (en) 1985-06-17 1992-06-25 Mark Philip Best Site-directed antibody conjugates, and their preparation
WO1989004838A1 (en) * 1987-11-25 1989-06-01 Immunex Corporation Interleukin-1 receptors
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5436155A (en) * 1991-12-31 1995-07-25 Arch Development Corporation Isolated DNA encoding a somatostatin receptor
US5789192A (en) 1992-12-10 1998-08-04 Schering Corporation Mammalian receptors for interleukin-10 (IL-10)
IL127891A0 (en) 1996-07-12 1999-10-28 Genentech Inc Chimeric heteromultimeter adhesins
US5843697A (en) 1996-07-17 1998-12-01 University Of Medicine And Dentistry Of New Jersey Cells expressing IL-10 receptor and the CRFB4 gene product, an IL-10 receptor accessory protein
US5985614A (en) * 1996-08-30 1999-11-16 Human Genome Sciences, Inc. Polynucleotides encoding interleukin-19
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
WO2000078961A1 (en) 1999-06-23 2000-12-28 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6486301B1 (en) 1997-07-16 2002-11-26 Human Genome Sciences, Inc. Interleukin-20
JP2001510035A (ja) 1997-07-16 2001-07-31 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド インターロイキン−２０
US5965704A (en) 1997-08-05 1999-10-12 Zymogenetics, Inc. Class two cytokine receptor-11
EP1009762A2 (en) * 1997-08-06 2000-06-21 ZymoGenetics, Inc. Lipocalin homologs
US6551799B2 (en) 1999-12-07 2003-04-22 Genentech, Inc. Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
CN1618969A (zh) 1997-11-26 2005-05-25 津莫吉尼蒂克斯公司 哺乳动物细胞因子样多肽－10
US6576743B1 (en) * 1997-11-26 2003-06-10 Zymogenetics, Inc. Mammalian cytokine-like polypeptide-10
DE69918946T2 (de) 1998-01-23 2005-07-28 Immunex Corp., Seattle Rezeptoren für il-18
WO1999046379A2 (en) 1998-03-09 1999-09-16 Schering Corporation Human receptor proteins; related reagents and methods
EP1490386B1 (en) 1998-03-10 2008-08-13 Genentech, Inc. Novel polypeptide and nucleic acids encoding the same
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
US6982320B2 (en) 1998-03-19 2006-01-03 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
WO1999061630A2 (en) 1998-05-26 1999-12-02 Regeneron Pharmaceuticals, Inc. Chimeric molecules comprising an extracellular ligand binding domain of a receptor and an ige fc or constant region, and their use in an assay system
ES2207278T3 (es) 1998-07-28 2004-05-16 Micromet Ag Heterominicuerpos.
NZ531664A (en) 1998-09-01 2005-07-29 Genentech Inc Pro1317 polypeptides and sequences thereof with homology to the semaphorin B glycoprotein family
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
AU760224B2 (en) 1998-10-26 2003-05-08 Wyeth Isolated nucleic acid molecules which encode T cell inducible factors (TIFs), the proteins encoded, and uses thereof
US6274710B1 (en) * 1998-10-26 2001-08-14 Ludwig Institute For Cancer Research Antibodies which specifically bind T Cell inducible factors (TIFs)
EP1141008A1 (en) 1998-12-31 2001-10-10 Millennium Pharmaceuticals, Inc. Class ii cytokine receptor-like proteins and nucleic acids encoding them
ES2295026T3 (es) 1999-04-28 2008-04-16 Genetics Institute, Llc Proteinas gil-19/ae289 humanas y polinucleotidos que codifican las mismas.
CA2373231A1 (en) 1999-05-19 2000-11-23 Incyte Genomics, Inc. Extracellular signaling molecules
AU5047600A (en) 1999-05-27 2000-12-18 Schering Corporation Mammalian interleukin-10 homologs: il-d110 and il-d210
ATE448246T1 (de) 1999-06-15 2009-11-15 Genentech Inc Sekretierte und transmembran-polypeptide sowie nukleinsäuren zu deren kodierung
WO2001004304A1 (en) 1999-07-07 2001-01-18 Zymogenetics, Inc. Human cytokine receptor
AU7573000A (en) 1999-09-01 2001-03-26 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU1919201A (en) 1999-11-18 2001-05-30 Schering Corporation Mammalian receptor proteins; related reagents and methods
WO2001040467A1 (en) * 1999-12-03 2001-06-07 Zymogenetics, Inc. Human cytokine receptor
DE60045139D1 (de) 1999-12-23 2010-12-02 Zymogenetics Inc Löslicher Interleukin-20-Rezeptor
US6610286B2 (en) * 1999-12-23 2003-08-26 Zymogenetics, Inc. Method for treating inflammation using soluble receptors to interleukin-20
EP1743648B1 (en) 1999-12-23 2010-03-03 ZymoGenetics, Inc. Method for treating inflammation
EP1242600B1 (en) 1999-12-23 2010-03-03 ZymoGenetics, Inc. Cytokine zcyto18
NZ523122A (en) 2000-06-22 2004-06-25 Smithkline Beecham Corp Polypeptides and polynucleotides and methods of identifying agonists and antagonists in relation to treatment of diseases
JP2002015498A (ja) 2000-06-29 2002-01-18 Fujitsu Ltd センス電流の設定方法
CA2418950A1 (en) * 2000-08-08 2002-02-14 Zymogenetics, Inc. Soluble zcytor 11 cytokine receptors
ATE549347T1 (de) 2000-09-08 2012-03-15 Schering Corp Gene von säugetiere, und damit verbundene reagentien, methoden
US7855269B2 (en) * 2000-09-15 2010-12-21 Zymogenetics, Inc. Method for treating inflammation
US7268223B2 (en) 2000-09-22 2007-09-11 Wyeth Isolated nucleic acid molecules which encode a soluble IL-TIF receptor or binding protein which binds to IL-TIF/IL-22, and uses thereof
US20030022827A1 (en) * 2000-09-25 2003-01-30 Bertram Weiss Three new members of the cytokine receptor family class 2
EP1191035A3 (de) 2000-09-25 2002-04-17 Schering Aktiengesellschaft Drei Mitglieder der Zytokinrezeptorfamilie Klasse II
AU2002249948B2 (en) 2001-01-12 2007-08-23 Genetics Institute, Llc Type 2 cytokine receptor and nucleic acids encoding same
EP1390060A2 (en) 2001-01-26 2004-02-25 Eli Lilly And Company Use of lp82 to treat body weight disorders
NZ527396A (en) 2001-02-23 2007-12-21 Genetics Inst Llc Antibodies and fragments thereof for the binding of IL-22 and use therefore for treating inflammatory disorders
JP2005506287A (ja) 2001-02-28 2005-03-03 イーライ・リリー・アンド・カンパニー 造血障害を治療するためのｌｐ８２の使用
EP1370676A4 (en) * 2001-03-02 2004-09-22 Zymogenetics Inc CYTOKIN RECEPTOR FROM MOUSE
CA2440596C (en) * 2001-03-09 2011-05-24 Zymogenetics, Inc. Soluble heterodimeric cytokine receptor
US20040086908A1 (en) 2002-03-07 2004-05-06 Chandrasekher Yasmin A. Soluble heterodimeric cytokine receptor
EP1373508B1 (en) 2001-03-27 2013-04-24 ZymoGenetics, Inc. Human cytokine receptor
EP2335728A1 (en) 2001-05-11 2011-06-22 Ludwig Institute for Cancer Research Ltd. Specific binding proteins and uses thereof
EP1439850A4 (en) 2001-10-22 2006-05-03 Lilly Co Eli SOLUBLE PROTEINS THAT RESIST CYTOKIN SIGNAL TRANSFER PATHS
DE10154579A1 (de) 2001-11-07 2003-05-28 Medigene Ag Topikale Verwendung von Cytokinen und Chemokinen zur Behandlung von viralen oder mykotischen Hauterkrankungen oder Tumorerkrankungen
WO2003051384A1 (en) 2001-12-17 2003-06-26 Zymogenetics, Inc. Method for treating cervical cancer
US20040236075A1 (en) 2002-07-24 2004-11-25 Laure Dumoutier Novel glass II cytokine receptors, and uses thereof
US20060134756A1 (en) * 2003-03-24 2006-06-22 Wenfeng Xu Anti-IL-20 antibodies and binding partners and methods of using in inflammation
EP1697418A2 (en) * 2003-11-21 2006-09-06 ZymoGenetics, Inc. Anti-il-20 receptor antibodies and binding partners and methods of using in inflammation
US7537761B2 (en) * 2004-10-22 2009-05-26 Zymogenetics, Inc. Anti-IL-22RA antibodies and binding partners and methods of using in inflammation
EP2512511B1 (en) * 2009-11-19 2015-01-07 Merck Serono S.A. Humanized antibodies against human il-22ra

Also Published As

Publication number Publication date
UA96122C2 (ru) 2011-10-10
US7871616B2 (en) 2011-01-18
PT1812476E (pt) 2010-11-08
IL182503A0 (en) 2007-09-20
NO20072602L (no) 2007-07-23
WO2006047249A1 (en) 2006-05-04
IL207146A (en) 2012-06-28
EP1812476B1 (en) 2010-07-21
AU2005299809A2 (en) 2006-05-04
EA015706B1 (ru) 2011-10-31
ATE474856T1 (de) 2010-08-15
EA200700916A1 (ru) 2007-10-26
JP2008517922A (ja) 2008-05-29
US8124088B2 (en) 2012-02-28
CA2584157A1 (en) 2006-05-04
US20090220519A1 (en) 2009-09-03
EP1812476A1 (en) 2007-08-01
CA2584157C (en) 2014-10-14
US20060141582A1 (en) 2006-06-29
US20120156210A1 (en) 2012-06-21
DE602005022475D1 (de) 2010-09-02
CY1110843T1 (el) 2015-06-10
US8536309B2 (en) 2013-09-17
MX2007004770A (es) 2007-11-22
ES2347672T3 (es) 2010-11-03
AU2005299809B2 (en) 2010-12-02
JP4898691B2 (ja) 2012-03-21
BRPI0516975A (pt) 2008-09-30
HK1110333A1 (en) 2008-07-11
KR20070084486A (ko) 2007-08-24
ZA200704125B (en) 2008-09-25
AU2005299809A1 (en) 2006-05-04
IL207146A0 (en) 2010-12-30
CN101198625A (zh) 2008-06-11
US20130315919A1 (en) 2013-11-28
KR101238684B1 (ko) 2013-03-04
US7537761B2 (en) 2009-05-26
US20100210825A1 (en) 2010-08-19
IL182503A (en) 2012-01-31

Similar Documents

Publication Publication Date Title
DK1606317T3 (da) Anti-IL-22RA-antistoffer og bindingspartnere samt fremgangsmåder til anvendelse ved inflammation
DK1812476T3 (da) Anti-IL-22RA-antistoffer og bindingspartnere samt fremgangsmåder til anvendelse ved inflammation
WO2006086396A3 (en) Anti-il-20, anti-il-22 and anti-il-22ra antibodies and binding partners and methods of using in inflammation
MXPA06014465A (es) Zcytor14 soluble, anticuerpos anti-zcytor14 y moleculas de union y metodos de uso en inflamacion.
WO2005052000A3 (en) Anti-il-20 antibodies and binding partners and methods of using in inflammation
DK1931697T3 (da) IL-17A og IL-17F-antagonister og fremgangsmåder til anvendelse af disse
DK1553975T3 (da) Optimerede Fc-varianter og fremgangsmåder til generering heraf.
NO20083712L (no) Peptider som blokkerer bindingen av IGG til FCRN
WO2004045525A3 (en) Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation.
IL192950A0 (en) Soluble il-17rcx4 and methods of using in inflammation
WO2008049070A3 (en) Il-17c antagonists and methods of using the same
EA200700823A1 (ru) Растворимый zcytor21, анти-zcytor21 антитела и связывающие партнёры и способы применения при воспалении
WO2005099755A3 (en) Methods of treating autoimmune and inflammatory diseases
WO2007076422A3 (en) Antibodies against interleukin-22 binding protein and its uses